• Home
  • Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.

Author List
Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN
Publication
JCI insight
Publication ID (Profile URL)
https://researcherprofiles.org/profile/676376915
Publication Year
2025
PubMed ID
40985888
Publication Title
Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN. Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma. JCI Insight. 2025 Sep 23; 10(18).
Publication Medline TA
JCI Insight
Date
2025-09-23